StockTipsArenaBeta

BUY Glenmark Pharmaceuticals — Rajesh Satpute

BUYGlenmark Pharmaceuticals
Glenmark Pharmaceuticals share price target & all analyst calls

byRajesh SatputeHorizon: NA (inferred Intraday)3 Jul 2026, 9:50 am ISTvia CNBC Awaaz.

Entry₹2,219.5Inferred
Target₹2,260
Total upside +1.82% (call closed)
Stop loss₹2,200-0.88% risk
Exit₹2,2003 Jul 2026, 10:54 am
Stop-loss hit-0.88%
Follow Rajesh Satpute for new calls(8% target hit, 124 closed calls)Get alertsWatch GLENMARK for new buy/sell callsGet alerts

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 25 Oct, 10:49 pm IST
1 supporting0 opposing
Supports the BUY call (1)

Glenmark Pharmaceuticals Ltd is advancing its Multi-Country Phase 3 Clinical Trial of Trastuzmab rezetecan in Platinum-Resistant Ovarian Cancer.

BSE · Company Update·2 Jul · yesterday

(opens in new tab)
Neutral / worth noting (0)

Nothing found in this tip’s window yet.

Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Glenmark Pharmaceuticals

All analyst calls on Glenmark Pharmaceuticals

More from Rajesh Satpute

Every call and its outcome